Celyad Oncology SA
CYAD
Company Profile
Business description
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.
Contact
Rue Edouard Belin 2
Axis Business Park
Brabant Wallon
Mont-Saint-Guibert1435
BELT: +32 10394100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
39
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,243.80 | 12.80 | -0.14% |
| CAC 40 | 7,974.85 | 3.07 | 0.04% |
| DAX 40 | 24,385.78 | 7.49 | 0.03% |
| Dow JONES (US) | 46,602.98 | 91.99 | -0.20% |
| FTSE 100 | 9,483.58 | 4.44 | 0.05% |
| HKSE | 26,957.77 | 183.15 | -0.67% |
| NASDAQ | 22,788.36 | 153.30 | -0.67% |
| Nikkei 225 | 47,950.88 | 6.12 | 0.01% |
| NZX 50 Index | 13,552.12 | 20.83 | 0.15% |
| S&P 500 | 6,714.59 | 25.69 | -0.38% |
| S&P/ASX 200 | 8,947.60 | 10.80 | -0.12% |
| SSE Composite Index | 3,882.78 | 20.25 | 0.52% |